Treatment of Mixed Chimerism After Hematopoietic Stem Cell Transplantation in Patients with Thalassemia Major

Author:

Liao Jianyun1,Liang Shimin2,Chen Jingtao3,Liu Xiaoting4,Xia Yuqian5,He Jujian5,Zhang Weiwei5,Pu Chaoke1,He Lan1,He Yuelin1,Feng Xiaoqin4,Wu Xuedong4,Li Chunfu1

Affiliation:

1. Nanfang-Chunfu Children’s Institute of Hematology and Oncology, Taixin Hospital, Dongguan, China; Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China

2. Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China

3. Department of Pediatrics, Southwest Medical University, Luzhou, China

4. Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China

5. Nanfang-Chunfu Children’s Institute of Hematology and Oncology, Taixin Hospital, Dongguan, China

Abstract

Background: Incomplete donor cell chimerism often occurs in thalassemia transplant due to host cells remain or reappear overtime, which is termed as mixed chimerism (MC). Objective: To compare the immunosuppression withdrawal (ISW) and donor lymphocyte infusion (DLI) in the correction of mixed chimerism (MC) after thalassemia transplantation. Methods: Eighty-seven patients with post-transplant MC admitted in our center from January 2010 to December 2019 were analyzed. Among them donor cells of 90%-95% and 75%-89% were classified as MC1 and MC2 respectively. MC3 donor cells <75%. The incidence and correction rate of MC, the occurrence rate of graft versus host disease (GVHD), timing of DLI were studied. Results: DLI was associated with higher correction rates and higher GVHD than ISW. In MC1 group, higher GVHD occurred in early and intermediate stage (<I>P</I> = 0.024/0.023) than ISW. In MC2 group, DLI in late stages had higher correction rates than ISW (<I>P</I> = 0.001). Conclusion: ISW was the primary strategy for MC1 patients. DLI should be given to the late-stage MC2 patients quickly. The earlier the treatment is provided, regardless of ISW or DLI, the more likely that patients develop GVHD.

Publisher

Science Publishing Group

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3